Efficacy and safety of the all-oral bedaquiline-containing regimen as treatment for pediatric multidrug/rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study

References

• Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016;16(10):1193–1201. doi: 10.1016/S1473-3099(16)30132-3
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report 2021. Geneva (Switzerland): WHO. [cited 2022 Mar 17]. Available from: https://www.who.int/publications/i/item/9789240037021
   Google Scholar
• Tao NN, He XC, Zhang XX, et al. Drug-resistant tuberculosis among children, China, 2006-2015. Emerg Infect Dis. 2017;23(11):1800–1805. doi: 10.3201/eid2311.170234
   PubMed Web of Science ®Google Scholar
• Song WM, Li YF, Liu YX, et al. Drug-resistant tuberculosis among children: a systematic review and meta-analysis. Front Public Health. 2021;9:721817. doi: 10.3389/fpubh.2021.721817
   PubMed Web of Science ®Google Scholar
• Harausz Elizabeth P, Garcia-Prats AJ, Seddon James A, et al. New and repurposed drugs for pediatric multidrug-resistant tuberculosis. Practice-based recommendations. Am J Respir Crit Care Med. 2017;195(10):1300–1310. doi: 10.1164/rccm.201606-1227CI
   PubMed Web of Science ®Google Scholar
• Harausz Elizabeth P, Anthony J G-P, Stephanie L, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLOS Med. 2018;15:e1002591. doi: 10.1371/journal.pmed.1002591
   PubMed Web of Science ®Google Scholar
• Garcia-Prats AJ, Purchase SE, Osman M, et al. Pharmacokinetics, safety, and dosing of novel pediatric levofloxacin dispersible tablets in children with multidrug-resistant tuberculosis exposure. Antimicrob Agents Chemother. 2019;63:e01865–18. doi: 10.1128/AAC.01865-18
   PubMed Web of Science ®Google Scholar
• Adtke KK, Hesseling AC, Winckler JL, et al. Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children. Clin Infect Dis. 2021;74(8):1372–1381. doi: 10.1093/cid/ciab641
   Web of Science ®Google Scholar
• Garcia-Prats AJ, Schaaf HS, Draper HR, et al. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: combined data from two prospective observational studies. PLOS Med. 2019 Apr 30;16(4):e1002789. doi: 10.1371/journal.pmed.1002789
   PubMed Web of Science ®Google Scholar
• WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment [M]. Genevia: World Health Organization; 2019. Available from:https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf
   Google Scholar
• The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. Management of Drug-Resistant Tuberculosis in Children: A Field Guide, 4th ed. Boston (MA USA): The Sentinel Project for Pediatric Drug-Resistant Tuberculosis; 2018 [cited 2020 Nov 24]. Available from: http://sentinelproject.org/wp-content/uploads/2019/02/Updated_DRTB-Field-Guide-2019-V3.pdf
   Google Scholar
• World Health Organization. Rapid Communication on Updated Guidance on the management of tuberculosis in children and adolescents. Geneva (Switzerland): World Health Organization; 2021.
   Google Scholar
• Achar J, Cathy H, Cavalheiro Ana P, et al. Off-label use of bedaquiline in children and adolescents with multidrug-resistant tuberculosis. Emerg Infect Dis. 2017;23:1711–1713. doi: 10.3201/eid2310.170303
   PubMed Web of Science ®Google Scholar
• Chines Anti-tuberculosis Association. Chemotherapy guidelines on drug-resistant tuberculosis. Chin Anti-TB J. 2019;2019(37(5):421–469.
   Google Scholar
• World Health Organization (WHO). WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (WHO/HTM/TB/2016.4). Geneva: WHO; 2016. Available from: www.apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf
   Google Scholar
• WHO operational handbook on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020.
   Google Scholar
• Zhang SJ, Yang Y, Sun WW, et al. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory MDR/RR/XDR-tuberculosis: a retrospective cohort study in east China. BMC Infect Dis. 2022 Aug 29;22(1):715. doi: 10.1186/s12879-022-07693-9
   PubMed Web of Science ®Google Scholar
• Dheda K, Gumbo T, Maartens G, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5(4):291–360. doi: 10.1016/S2213-2600(17)30079-6
   Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009 Jun 4;360(23):2397–2405. doi: 10.1056/NEJMoa0808427
   PubMed Web of Science ®Google Scholar
• Francesco P, Canto Giulia D, Piero V, et al. Treatment of multidrug -resistant and extensively drug-resistant tuberculosis in children: the role of bedaquiline and Delamanid. Microorganisms. 2021;9(5):1074. doi: 10.3390/microorganisms9051074
   PubMed Web of Science ®Google Scholar
• Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005 Jan 22-28;365(9456):318–326. doi: 10.1016/S0140-6736(05)17786-1
   PubMed Web of Science ®Google Scholar
• World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision: updated December 2014 and January 2020. World Health Organization. 2013 [cited 2021 Oct 6]. Available from: https://apps.who.int/iris/handle/10665/79199
   Google Scholar
• Seddon James A, Carlos M P-V, Simon SH, et al. Consensus statement on Research definitions for drug-resistant tuberculosis in children. J Pediatric Infect Dis Soc. 2013;2:100–109. doi: 10.1093/jpids/pit012
   PubMedGoogle Scholar
• Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9(6):640–645.
   PubMed Web of Science ®Google Scholar
• National department of HealthInterim clinical Guidance for the Implementation of injectable-free regimens for rifampicin-resistant tuberculosis in adults, adolescents and children. Available from: https://www.tbonline.info/media/uploads/documents/dr_tb_clinical_guidelines_for_rsa_september_2018.pdf
   Google Scholar
• Department of Health and Human Services. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events: corrected version 2.1 July 2017. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf
   Google Scholar
• Shibeshi W, Sheth AN, Admasu A, et al. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study. BMC Pharmacol Toxicol. 2019;20(1):31. doi: 10.1186/s40360-019-0313-y
   PubMedGoogle Scholar
• Guideline IHT. Clinical safety data management: definitions and standards for expedited reporting E2A. In: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use; Geneva; 1994.
   Google Scholar
• World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis interim policy Guidance; WHO/HTM/TB/2013.6. Geneva (Switzerland): WHO; 2013.
   Google Scholar
• Olaru ID, Heyckendorf J, Andres S, et al. Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis. Eur Respir J. 2017;49(5):1700742. doi: 10.1183/13993003.00742-2017
   PubMed Web of Science ®Google Scholar
• Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J. 2017 Nov 16;50(5):1701462. doi: 10.1183/13993003.01462-2017
   PubMed Web of Science ®Google Scholar
• Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect. 2021;27(4):597–602. doi: 10.1016/j.cmi.2020.06.004
   PubMed Web of Science ®Google Scholar
• Ndjeka N, Campbell JR, Meintjes G, et al. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Lancet Infect Dis. 2022 Jul;22(7):1042–1051. doi: 10.1016/S1473-3099(21)00811-2
   PubMed Web of Science ®Google Scholar
• Zignol M, Dean AS, Alikhanova N, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016;16(10):1185–1192. doi: 10.1016/S1473-3099(16)30190-6
   PubMed Web of Science ®Google Scholar
• Swanepoel J, Klassina Z, van der Zalm Marieke M, et al. Understanding the biology, morbidity and social contexts of adolescent tuberculosis: a prospective observational cohort study protocol (teen TB). BMJ Open. 2022;12:e062979. doi: 10.1136/bmjopen-2022-062979
   PubMed Web of Science ®Google Scholar